scispace - formally typeset
W

Wouter van Rheenen

Researcher at Utrecht University

Publications -  65
Citations -  7700

Wouter van Rheenen is an academic researcher from Utrecht University. The author has contributed to research in topics: Amyotrophic lateral sclerosis & Genome-wide association study. The author has an hindex of 28, co-authored 53 publications receiving 5929 citations. Previous affiliations of Wouter van Rheenen include University Medical Center Utrecht.

Papers
More filters
Journal ArticleDOI

A reference panel of 64,976 haplotypes for genotype imputation

Shane A. McCarthy, +117 more
- 22 Aug 2016 - 
TL;DR: A reference panel of 64,976 human haplotypes at 39,235,157 SNPs constructed using whole-genome sequence data from 20 studies of predominantly European ancestry leads to accurate genotype imputation at minor allele frequencies as low as 0.1% and a large increase in the number of SNPs tested in association studies.

A reference panel of 64,976 haplotypes for genotype imputation

Shane A. McCarthy, +110 more
TL;DR: In this article, a reference panel of 64,976 human haplotypes at 39,235,157 SNPs constructed using whole-genome sequence data from 20 studies of predominantly European ancestry is presented.
Journal ArticleDOI

Genome-wide association analyses identify new risk variants and the genetic architecture of amyotrophic lateral sclerosis

Wouter van Rheenen, +187 more
- 01 Sep 2016 - 
TL;DR: Evidence of ALS being a complex genetic trait with a polygenic architecture is established and the SNP-based heritability is estimated at 8.5%, with a distinct and important role for low-frequency variants (frequency 1–10%).
Journal ArticleDOI

Genome-wide Analyses Identify KIF5A as a Novel ALS Gene.

Aude Nicolas, +435 more
- 21 Mar 2018 - 
TL;DR: Interestingly, mutations predominantly in the N-terminal motor domain of KIF5A are causative for two neurodegenerative diseases: hereditary spastic paraplegia and Charcot-Marie-Tooth type 2.
Journal ArticleDOI

Prognosis for patients with amyotrophic lateral sclerosis: development and validation of a personalised prediction model

TL;DR: An externally validated model is developed to predict survival without tracheostomy and non-invasive ventilation for more than 23 h per day in European patients with ALS and could be applied to individualised patient management, counselling, and future trial design.